

REVIEW

Open Access



# Consensus on the Southeast Asian management of hypotension using vasopressors and adjunct modalities during cesarean section under spinal anesthesia

Grace Anne B. Herbosa<sup>1\*</sup>, Nguyen Ngoc Tho<sup>2</sup>, Angelina A. Gapay<sup>3</sup>, Suraphong Lorsomradee<sup>4</sup> and Cong Quyet Thang<sup>5</sup>

## Abstract

**Background and aims:** This consensus statement presents a comprehensive and evidence-based set of guidelines that modify the general European or US guidelines for hypotension management with vasopressors during cesarean delivery. It is tailored to the Southeast Asian context in terms of local human and medical resources, health system capacity, and local values and preferences.

**Methods and results:** These guidelines were prepared using a methodological approach. Two principal sources were used to obtain the evidence: scientific evidence and opinion-based evidence. A team of five anesthesia experts from Vietnam, the Philippines, and Thailand came together to define relevant clinical questions; search for literature-based evidence using the MEDLINE, Scopus, Google Scholar, and Cochrane libraries; evaluate existing guidelines; and contextualize recommendations for the Southeast Asian region. Furthermore, a survey was developed and distributed among 183 practitioners in the captioned countries to gather representative opinions of the medical community and identify best practices for the management of hypotension with vasopressors during cesarean section under spinal anesthesia.

**Conclusions:** This consensus statement advocates proactive management of maternal hypotension during cesarean section after spinal anesthesia, which can be detrimental for both the mother and fetus, supports the choice of phenylephrine as a first-line vasopressor and offers a perspective on the use of prefilled syringes in the Southeast Asian region, where factors such as healthcare features, availability, patient safety, and cost should be considered.

**Keywords:** Blood pressure measurement, Cesarean section, Ephedrine, Hypotension, Phenylephrine, Spinal anesthesia, Vasopressor

## Key recommendations for best clinical practice

Using the best available evidence, the 2016 ACC and AHA Clinical Practice Guideline Recommendation Classification Systems [1] were used to evaluate each of the following elements (Table 1).

\*Correspondence: gabansonherbosa@up.edu.ph

<sup>1</sup> Department of Anesthesiology, University of the Philippines College of Medicine, Manila, Philippines

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

**Table 1** Key recommendations for best clinical practices

Key recommendations	Strength of recommendations	References
Hypotension during SA needs prompt recognition and treatment, since it is frequent and has adverse effects on the mother and the fetus	High	[2, 3]
A systolic NIBP of < 80% of baseline is considered hypotension, and SBP must be maintained at > 90% of baseline	High	[2–4]
Vasopressor should be used to manage SA-associated hypotension	High	[4–6]
Phenylephrine should be used as the first-line of vasopressor treatment to maintain the desired SBP in the absence of bradycardia	High	[2, 5]
Phenylephrine can be given prophylactically to reduce the risk of hypotension and nausea and vomiting after SA	High	[2, 3, 7]
Phenylephrine may be administered as an infusion titrated at 25–50 µg/min after administration of SA, depending on blood pressure and heart rate with additional IV boluses if needed	High	[2, 3, 8]
Phenylephrine can be administered as a bolus of 50–100 µg on SA administration. For immediate management of hypotension, IV bolus of phenylephrine has a faster onset than an infusion	High	[2, 3]
Phenylephrine and ephedrine bolus should be administered using prefilled syringe since it prevents medication errors, creates less waste, improves patient safety, and allows long-term cost savings	High	[2, 9–11]
Intermittent IV boluses of 5–15 mg ephedrine must be administered in the presence of bradycardia and hypotension, but the cumulative dose before delivery should not exceed 15 mg to minimize fetal acidosis	High	[5, 12, 13]
Leg compression devices, manual left uterine displacement, wedge for left uterine displacement, and administration of 5HT <sub>3</sub> antagonists (e.g., ondansetron) may be used as prespinal measures to prevent hypotension after SA	Medium	[5, 14–17]
Crystalloid co-loading should commence together with prophylactic administration of vasopressors	Medium	[2, 3]
Noradrenaline (norepinephrine) infusion (starting rate can be 0.1 µg/kg/min) or bolus (5–10 µg) may be used in limited-resource areas (using a central line or temporarily in large-bore peripheral line)	Low	[18–21]
An anticholinergic agent (glycopyrrolate or atropine) may be used for significant bradycardia with hypotension	Low	[2, 22]

## Background

Spinal anesthesia (SA) is generally used for elective cesarean section [23]. A common consequence of the sympathetic vasomotor block caused by SA for cesarean section is hypotension, which occurs in up to 80–90% of cases, depending on the definition [24, 25]. SA often leads to a drop in blood pressure and bradycardia by inducing a sympathovagal imbalance toward parasympathetic tone [26]. Cardiac output studies have shown that SA has a biphasic effect, in which cardiac output initially increases following a reduction in afterload from arterial vasodilatation and subsequently decreases due to a reduced preload [2]. Hypotension affects both the mother and fetus, including maternal nausea, vomiting, dizziness, rare loss of consciousness, cardiac arrest, and death [27]; and fetal symptoms, including low Apgar scores and low umbilical arterial pH (umbilical acidosis), have been shown to be associated with the duration and severity of hypotension [28]. Hypotension may be related to maternal and neonatal morbidity. Thus, several methods have been investigated alone or in combination for its prevention and treatment [2]. Left uterine displacement has been used to reduce the effects of aortocaval compression [14]. Simply elevating the legs is not sufficient to reduce the incidence of hypotension [15]. Fluid preloading is often performed with varying results [16, 17]. However, fluid co-loading is universally accepted.

Nonpharmacological techniques have shown uncertain efficacy in effectively treating hypotension, and a vasopressor is often required during SA for cesarean section. Several factors must be considered in choosing an appropriate vasopressor, such as its efficacy in maintaining blood pressure, maternal non-cardiovascular effects, ease of use, direct and indirect fetal effects, availability, and cost [2].

The vasopressors commonly used to manage hypotension during SA are ephedrine and phenylephrine [2]. The use of ephedrine for obstetric patients is supported by evidence from animal studies, which have shown better maintenance of uteroplacental blood flow when ephedrine is used to increase maternal blood pressure [29]. However, ephedrine has several disadvantages, including a slow onset and a relatively long duration of action, making accurate titration of blood pressure potentially difficult [30]. Clinical studies have shown that ephedrine is associated with a dose-dependent tendency to lower fetal pH and base excess [31].

Phenylephrine is a potent direct-acting alpha-adrenergic agonist. Relatively high doses of phenylephrine may be required in pregnancy because of the often reduced pressor response to endogenous and exogenous vasoconstrictors [32]. However, fetal acidosis following the use of phenylephrine to maintain maternal blood pressure and prevent symptoms has not been demonstrated [33].

This evidence-based consensus statement aims to translate findings from research into recommendations for clinical practice that, when implemented, can improve outcomes.

## Methods


This manuscript describes the several stages used to reach a consensus among selected experts in anesthesia after a careful review of existing evidence. A flow diagram of the consensus procedures, including the systematic literature review and the modified Delphi process, is shown in Fig. 1.

The whole process included four virtual meetings, 3 months of offline work, and two rounds of votes.

### Literature review

This study conforms to the preferred reporting points for systematic reviews and meta-analyses [34]. The MEDLINE, Scopus, Google Scholar, and Cochrane libraries were explored for the systematic literature

review. A combination of subject headings and free-text terms was used. The search was limited to publications from 1970 to 2021. The quantitative and qualitative analysis of the literature were confined to parturients undergoing cesarean section under SA. We included the following interventions for hypotension: vasopressors (ephedrine, phenylephrine, norepinephrine, epinephrine), nonpharmacologic interventions (left lateral tilt, fluid co-loading, compression stockings, position changes), and pharmacological preventive strategies (local anesthetic dosage). Outcomes included maternal outcomes (presence of hypotension, degree of hypotension, duration of hypotension, nausea, and vomiting) and fetal outcomes (presence of acidosis, asphyxia, and death). During the initial search, 90 titles could be identified. After eliminating duplicates and irrelevant studies, the remaining 27 titles were reviewed, resulting in 18 titles being selected for analysis. In addition, five systematic reviews and one meta-analysis were considered.



### Modified Delphi process

A team of five anesthesiology experts from the Philippines, Vietnam, and Thailand were selected, based on their expertise assessed using a pedigree analysis, to define the relevant clinical questions, search for literature-based evidence, evaluate the available guidelines, and contextualize the recommendations for Southeast Asian (SEA) conditions. Furthermore, they compared the adapted guidelines with real-world practice through a survey shared with a representative panel of local practitioners to collect opinions, identify conflicting views, and determine best practices for the management of hypotension with vasopressors during cesarean section under SA based on current knowledge, evidence, and available treatments.

A group of 183 experts was selected and invited to participate in a web-based survey via email describing the aims and procedures. The survey was conducted online using SurveyMonkey® between June 2022 and September 2022. It consisted of 18 statements designed to gather the opinions of the members from the selected countries. The results of the survey were assessed using the percentage of responses for each statement on a Likert scale, which included “Strongly Agree”, “Agree”, “Disagree”, and “Strongly Disagree” response options. The consensus agreement was predefined as 80%. The analysis of the responses was performed by the panel members, and 17 consensus statements were developed and revised.

### Consensus recommendations

The literature review results combined with the modified Delphi survey contributed to the development of the consensus statement. Based on the best available evidence, the 2016 ACC and AHA Clinical Practice Guideline Recommendation Classification Systems [1] were used to evaluate each proposed recommendation. Each recommendation was rated in terms of its strength (weak or strong) and quality (high, moderate, low, very low) according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.

### Literature review

#### Definition of hypotension

There is no accepted definition of hypotension in the scientific literature. The incidence of hypotension varies depending on the chosen definition; even small alterations in the definition result in large differences in the incidence of hypotension [35]. The reported incidence of hypotension varies between 1.9% [36] and up to 80–90% [24, 25], a huge gap related to highly different definitions of hypotension between studies. In a 2010, systematic

review of the literature that addressed the wide range of definitions of hypotension in studies of women undergoing SA for cesarean section, Klör et al. [35] found that the two most common definitions of hypotension were defined by a drop of <80% from baseline or a combination of two criteria, i.e., SBP <100 mmHg or a drop of <80% from baseline. Other international studies on obstetric anesthesia favored a SBP <20% baseline [8, 37], SBP <90 mmHg [38], or a combined definition (SBP <20% baseline or SBP <90 mmHg) [39]. A survey of obstetric anesthetists in the UK found that the preferred absolute SBP thresholds were <90 mmHg or <100 mmHg [40]. In a recent (2018) international consensus statement on the treatment of spinal hypotension using vasopressors, the authors stated that mean arterial pressure (MAP) is a better indicator of organ perfusion, but should probably not be used because of the lack of supporting data [2]. They advise maintaining a SBP  $\geq$  90% of baseline until delivery of the newborn and reducing the number of SBP episodes to <80% of baseline. Treatment for values that fall below this level should be rapid, preferably with vasopressors [2]. Importantly, they refer to a reduced pressure from baseline, because women in labor show higher arterial pressure. Absolute values may lead to the underdiagnosis of hypotension. The SBP threshold for pregnancy-induced hypertension or preeclampsia is >140 mmHg [2].

#### Pathophysiology and consequences of hypotension

Nausea and vomiting occur significantly more frequently during SA for caesarean section than during non-obstetric surgery and are mainly caused by hypotension [41]. SA-induced hypotension is caused by arterial and venous vasodilatation that results from the sympathetic block, together with the paradoxical activation of cardioinhibitory receptors [2]. Acute hypotension activates vomiting centers by reducing cerebral perfusion and inducing transient brainstem ischemia [42]. This can also lead to transient cerebral hypoxia associated with a marked decrease in maternal cerebral blood volume, cerebral oxygen saturation, and oxygenation [43]. These effects are also consistent with the prevention of cerebral hypoxia and a reduction in the incidence of nausea by oxygen inhalation [44, 45]. Prolonged, severe maternal hypotension can cause dizziness and decreased consciousness [46], which is less likely to occur when a drop in blood pressure is immediately treated.

SA leads to an approximately 20% reduction in splanchnic blood flow, which is also notable in systemic hypotension [47]. Splanchnic hypoperfusion results in the release of emetogenic substances, such as serotonin from the digestive tract, another pathophysiological mechanism

of nausea, and vomiting [42]. Finally, sympathetic blockade by SA leads to an unopposed vagal effect, resulting in gastrointestinal hyperactivity [48].

Bradycardia, defined as a reduction of >20% heart rate at baseline after SA, must always be considered as a warning sign of an important hemodynamic compromise [49]. In serious bradycardia with hypotension, an anticholinergic (glycopyrrolate or atropine) may be required. However, current evidence is insufficient to recommend the routine use of glycopyrrolate for the prevention of hypotension [22].

Fetal perfusion depends on uteroplacental blood flow, which in turn depends on uterine perfusion. Newborns from mothers with SA-induced hypotension are significantly more acidotic [50]; however, the severity of hypotension plays a less important role than its duration [2].

#### **Pharmacology of vasopressor agents**

Vasopressors commonly used to prevent SA-induced hypotension include primarily the direct action of the selective  $\alpha_1$ -receptor agonist phenylephrine and the direct and indirect action of ephedrine [51]. Both epinephrine and norepinephrine are alternatives for the correction of hypotension and bradycardia that do not respond to ephedrine [52, 53].

#### **Phenylephrine**

At clinical doses, phenylephrine is a selective  $\alpha_1$ -receptor agonist and becomes a  $\beta$ -agonist at much higher doses [54]. It can also induce baroreceptor-mediated bradycardia when given at higher than required doses [2]. It counteracts SA-induced hypotension due to pronounced arterial vasoconstriction due to its actions as a  $\alpha_1$ -agonist [55]. An intravenous (IV) dose of phenylephrine shows an almost immediate onset of action and a duration of action of 5–10 min [56]. Phenylephrine shows a faster onset of action than ephedrine (40 vs. 90 s, respectively) [13]. A number of studies suggest that SA-induced hypotension is prevented by an intermittent bolus dose (ED95) of phenylephrine of at least 122–147  $\mu\text{g}$  [39, 57] administered intravenously; however, a 40–100  $\mu\text{g}$  bolus dose is still a common clinical practice [58]. Prophylactic infusions in the range of 25–100  $\mu\text{g}/\text{min}$  have been recommended. A fixed dose of 50  $\mu\text{g}/\text{min}$  can minimize the risk of a higher incidence of hypotension, reactive hypertension, bradycardia, and decreased cardiac output [8, 55, 58].

#### **Ephedrine**

Ephedrine has a weak direct  $\alpha$ - and  $\beta$ -agonistic effect; however, its indirect effect is greater because of the release of norepinephrine from sympathetic neurons [54]. It increases blood pressure by stimulating the

$\beta_1$ -receptor, resulting in increased heart rate and cardiac contractility, whereas the  $\alpha$ -agonist effect leads to peripheral vasoconstriction [59, 60]. Ephedrine crosses the placenta to a greater extent because of high-lipid solubility and undergoes less fetal metabolism and redistribution. This leads to increased fetal concentrations of lactate, glucose, and catecholamines, resulting to fetal acidemia due to stimulation of fetal adrenergic receptors. Its overall effect on fetal oxygen supply and demand balance may favor phenylephrine over ephedrine [61]. As a rescue vasopressor, a 5–15 mg bolus administered intravenously is most often recommended for treating hypotension following SA. The drug has a delayed onset of action and a longer duration of action of approximately 60 min. The depletion of presynaptic norepinephrine stores also leads to tachyphylaxis [62]. Thus, IV boluses are preferable for continuous IV infusion [2]. To avoid fetal acidemia, ephedrine is a poor choice and a maximum dose of 15 mg ephedrine is recommended, if it is the only vasopressor available.

#### **Norepinephrine**

Norepinephrine (noradrenaline) is a potent  $\alpha$ -adrenoceptor agonist and a weak  $\beta$ -adrenoceptor agonist. It is, therefore, an attractive option for maintaining maternal blood pressure with fewer adverse effects on heart rate and cardiac output. In addition, it shows the same efficacy as phenylephrine in preventing and treating SA-induced hypotension during cesarean delivery [63]. Blood pressure, stroke volume, and neonatal outcomes are similar for patients who receive norepinephrine or phenylephrine. Nonetheless, the incidence of maternal bradycardia is lower with norepinephrine [18]. Other studies have shown that norepinephrine may be an alternative to phenylephrine without adverse effects [19, 20]. However, data are still lacking, indicating that norepinephrine is a better alternative to phenylephrine regarding fetal acidemia. Also, the placental transfer is minimal compared to ephedrine.

#### **Epinephrine**

Relative to norepinephrine, epinephrine (adrenaline) has a high affinity for  $\alpha_1$ -,  $\beta_1$ -, and  $\beta_2$ -adrenergic receptors. The  $\beta$ -effects are predominant at low doses, whereas the  $\alpha_1$ -effects are significant at higher doses. [2]. The potent  $\beta$ -action of epinephrine could compensate for the reflex decrease in maternal heart rate and cardiac output during SA for cesarean section [52].

#### **Prevention of hypotension**

A large drop in blood pressure during a cesarean section can endanger both the mother and fetus. Therefore, it is essential to take measures to ensure optimal circulatory stability during a cesarean delivery [46]. Indeed, fetal



perfusion is dependent on uteroplacental blood flow, which is not autoregulated, making it directly dependent on the uterine perfusion pressure and inversely proportional to uterine vascular resistance [64]. There are several measures for preventing hypotension during SA for cesarean section that should be performed simultaneously. After administration of SA, crystalloid co-loading can begin with prophylactic administration of vasopressors [49]. The first option is phenylephrine infusion (syringe pump/infusion device) starting at 25–50  $\mu$ g per minute after the administration of SA and adjusted for blood pressure and heart rate. Therefore, additional IV bolus therapy may be required. The second option is phenylephrine, which is administered as a bolus during the administration of SA [65]. A prefilled syringe is preferred due to reduced medication errors, less wastage, and patient safety [66–68]. An alternative option is an ephedrine bolus administered upon administration of the spinal anesthetic [68]. A maximum dose of 15 mg ephedrine can be used to avoid fetal acidemia. In women with preexisting hypertension or preeclampsia, caution is advised before initiating pharmacological measures to prevent hypotension. Non-pharmacological measures to prevent hypotension include tilting the table to 30° and manually shifting the uterus to the left [2].

#### **Recognition of early hypotension**

Three consecutive noninvasive blood pressure (NIBP) measurements are required to obtain the mean baseline NIBP (systolic pressure). At the same time, three simultaneous heart rate measurements are required to obtain the baseline heart rate values. The alarm threshold of the NIBP monitoring system is then set to 90% of the baseline NIBP value, with automatic measurement every 1 min or less, at least until delivery [2]. Frequent and continuous communication with the parturient until delivery may allow early recognition of hypotension. Nausea and vomiting after SA are among the earliest clinical signs of hypotension, as is subjective discomfort of the parturient [41]. Sudden tachycardia immediately after SA may precede the recognition of hypotension [2].

#### **Vasopressor agent choices for hypotension management**

SA-associated hypotension in cesarean delivery should be primarily managed with vasopressors rather than fluids [46]. Maternal and fetal outcomes are better when vasopressors are administered prophylactically rather than reactively to treat hypotension. Availability, cost, and benefit must be considered when selecting vasopressors for the treatment and prevention of hypotension (phenylephrine, ephedrine, norepinephrine, epinephrine). Phenylephrine has important properties for the treatment of spinal hypotension: (1) it is an  $\alpha$ -adrenergic

agonist that acts directly on the decrease in systemic vascular resistance after SA [38], (2) it has a faster onset of action than ephedrine [12], (3) ephedrine is associated with a five-fold increased risk of fetal acidosis [69], and (4) ephedrine is more likely to cross the placenta and increase lactate, glucose, and catecholamine concentrations in the fetal circulation than is phenylephrine [61]. Therefore, phenylephrine is the first-line vasopressor agent of choice for hypotension due to SA for cesarean section in parturients with normal heart rates. Given the maternal response to SA (decreased systemic vascular resistance), the use of ephedrine is not appropriate from the physiological point of view because of its beta-adrenergic agonist properties [26]. For bradycardia, however, ephedrine is the drug of choice. Adrenaline (epinephrine and norepinephrine) is the preferred choice for bradycardia with hypotension that does not respond to ephedrine treatment. If hypotension persists despite aggressive interventions, causes other than SA should be considered.

#### **Vasopressor agent form for hypotension management**

In a randomized double-blind clinical trial evaluating hemodynamic changes, administration of phenylephrine as an infusion did not provide clinical benefits compared with bolus treatment. The bolus regimen maintained maternal arterial blood pressure near baseline in the first minutes after SA, whereas the infusion treatment required a higher total dose of phenylephrine to have the same effect during the period prior to delivery [70]. In a recent study comparing bolus doses of 50  $\mu$ g phenylephrine with a fixed infusion rate of 50  $\mu$ g/min of the same prophylactically administered drug, the infusion group showed better control of blood pressure than the bolus group, although the neonatal outcome was similar in both groups [71]. Another study compared variable infusion, fixed on-and-off infusion, and intermittent boluses of phenylephrine for the prophylaxis of maternal hypotension during cesarean delivery. It concluded that the fixed on-and-off infusion regimen of phenylephrine provided the same cardiovascular profile as variable infusion and avoided unnecessary medical interventions and calculations [72].

Prophylactic administration of ephedrine via the intramuscular route is highly debatable because the systemic absorption and peak effect are difficult to predict, which can lead to rebound hypertension [73]. Although large doses are used, the IV route is more controllable and effective [62]. Studies using a prophylactic bolus or infusions of IV ephedrine have shown their efficacy in preventing episodes of hypotension [74–76]. A prophylactic bolus of 12 mg ephedrine administered intravenously at the time of intrathecal block and rescue boluses have

been shown to result in a lower incidence of hypotension after SA during elective cesarean section than IV rescue boluses alone [76].

Studies on the use of norepinephrine during SA for cesarean delivery have reported delivery by computer-guided infusion, fixed-rate infusion, and intermittent boluses [18–20]. Manually controlled infusion of norepinephrine in the range of 0–5 µg/min was proven to be effective in reducing the incidence of hypotension and provided more stable blood pressure control than for a control group receiving rescue boluses of 5 µg norepinephrine to treat hypotension when it occurred [21]. Recently, low-dose epinephrine infusion was also shown to prevent maternal hypotension and uteroplacental perfusion during SA cesarean delivery [52].

#### **Vasopressor agent administration routes**

Vasopressors have been delivered via a central venous catheter (CVC) due to potential extravasation concerns and subsequent tissue necrosis [77]. However, the use of vasopressors via peripheral IV catheters (PiVCs) rather than CVC has been growing [77].

A systematic review of the safety of vasopressor drug administration via PiVCs concluded that extravasation is rare and unlikely to lead to major complications [78]. All vasopressor agents can be administered through large peripheral IV or CVC lines, based on these current data. Epinephrine and norepinephrine should be administered via a CVC line. However, in urgent cases, these agents may be administered temporarily via a peripheral IV line. Norepinephrine should be diluted in water with 5% dextrose (D5W) [79].

#### **Prompt hypotension management**

##### ***Non-pharmacological measures***

The debate is still ongoing on whether the patient's height influences the block level in SA. Several studies have reported no statistical correlation between block level and height [80–82]. Huang et al. [83] showed that the dose of local anesthetic was not adjusted according to height in many studies. This is an important point for the population of SEA, where most parturients are small. The block level was related to the length of the vertebral column [84]. Although height accounted for only 10.6% of the variation in vertebral column length, there was a statistically significant correlation between these two parameters [82]. Thus, block level should be chosen based on height, as supported by two studies [85, 86]. Huang et al. showed that the block level was highly dependent on the height of the parturient when using a low dose of bupivacaine [83]. A lower dose of local anesthetic results in less blockade and reduces the incidence

of hypotension at SA; however, it may cause incomplete analgesia and muscle relaxation [87].

A recent prospective observational study showed that there is a 3.26-fold higher risk of hypotension in the supine position before SA than in the full lateral position before SA [88]. Previous studies demonstrated that the incidence of hypotension was low if the parturient was in a fully left lateral position until the start of surgery [89, 90]. Furthermore, transferring a full-term parturient from the left lateral position to the left tilt position prevented aortocaval compression better than transferring them from the supine position to the left tilt position [91].

Maternal hyperoxia increases the fetal partial pressure of oxygen and improves the acid–base status [92]; supplemental oxygen should be administered via a nasal cannula or face mask while conducting an SA. Because an adequate sensory block for surgery should cover the fourth thoracic dermatome, there is a concomitant worsening of pulmonary function. Significant decreases in peak expiratory flow, forced vital capacity, forced expiratory volume in one second, and forced expiratory flow in the midrange of forced vital capacity were demonstrated after SA in the supine position [93]. These conditions and SA-induced hypotension can cause fetal acidemia [77]. Therefore, supplemental oxygen in an elective cesarean section is indicated in clinical practice for the well-being of the fetus.

The second peripheral IV line or CVC was recommended, one for rapid fluid exchange and the other for drug administration, including vasopressors and atropine. In addition to standard monitors, an arterial line may be considered in high-risk patients for hemodynamic measurements, including pulse contour and cardiac output [68]. A trained nurse or doctor should be in the theater for help and advice.

Another aspect of treatment is the maintenance of normothermia. It is estimated that perioperative hypothermia occurs in >60% of patients who receive SA for cesarean delivery [94–96]. In these patients it significantly impairs thermal autoregulation by inhibiting vasomotor responses and tremors, even beyond the level of sensory block, causing thermal redistribution of heat from the core to peripheral tissues [97, 98]. In the absence of strategies to preserve normothermia, patients become hypothermic in the first 30–40 min of surgery and remain hypothermic postoperatively [99]. Hypothermia increases the risk of cardiovascular events, such as arrhythmias, myocardial ischemia, coagulopathy, greater blood loss, requiring transfusions, wound infections that show delayed healing due to decreased antibody and cell-mediated immune responses, and oxygen availability in peripheral wound tissues. In addition, changes in pH alter the

kinetics and effects of various anesthetics and paralyzing agents, increase thermal discomfort, and are associated with delayed postanesthetic recovery [94, 100].

### **Pharmacological measures**

Fluid loading is another aspect of the antihypotensive strategy. It can counteract the relative hypovolemia due to venodilation and help maintain hemodynamic stability by increasing venous return [101]. Despite the effectiveness of phenylephrine, a significantly higher frequency of hypotension has been observed in the absence of fluid administration [36]. In addition, the CAESAR study showed that a mixed infusion of hydroxyethyl starch (HES) and Ringer's lactate more effectively reduces maternal hypotension than Ringer's lactate infusion alone when combined with IV phenylephrine boluses. In addition, the reduction in the incidence of severe symptomatic hypotension or both was even greater [102]. Another study revealed that the co-load strategy is superior to preloading for preventing maternal hypotension [103]. A survey showed that many obstetric anesthetists favor fluid therapy in their clinical practice [104]. However, crystalloids are required in large volumes (> 15 ml/kg) to decrease the incidence of hypotension [105]. These large volumes result in adverse effects, such as increased central venous pressure [106], blood dilution, leading to a decrease in oxygen transport capacity [107], and the release of atrial natriuretic peptide, initiating diuresis, thus reducing the effect of volume load on blood pressure [108].

The first-line treatment for hypotension is early intervention with phenylephrine if the heart rate is maintained during SA. In one study, phenylephrine infusions (25–50 µg/min) maintained baseline maternal hemodynamics and were used in conjunction with SA. Vigilant use of phenylephrine bolus infusions (50–100 µg) targeting the maternal heart rate as a surrogate for cardiac output is also effective, especially in resource-limited settings. Alternatively, phenylephrine infusions (< 25 µg/min) with boluses (50–100 µg) can be used [65].

An IV 5–15 mg bolus of ephedrine can be used as a rescue vasopressor for bradycardia. Its clinical action is primarily due to the indirect release of norepinephrine from postganglionic nerve endings. The drug shows a delayed onset of action and a longer duration of action of approximately 60 min [109]. Moreover, the cumulative dose before delivery should not exceed 15 mg to avoid fetal acidosis.

Epinephrine or norepinephrine may be administered for persistent hypotension. However, the use of such a potent agent in non-intensive care settings, such as the labor ward, has raised concerns [2]. At a dose of 0.1 µg/kg/min, epinephrine infusion was more effective than phenylephrine at maintaining blood pressure close to

baseline during SA, with a lower decrease in maternal heart rate and cardiac output [52]. The use of norepinephrine to prevent and treat hypotension during SA is new, and data in the literature are scarce. Continuous computerized infusion of norepinephrine (5 µg/ml) and phenylephrine (100 µg/ml) to prevent hypotension during SA have been studied. Norepinephrine was more effective than phenylephrine in maintaining blood pressure, as well as higher cardiac output and heart rate [18]. Intermittent IV norepinephrine boluses to prevent SA-induced hypotension during elective cesarean delivery may also be considered. A recent study suggested a 90% effective dose (ED90) of 6 µg for this situation, which was not associated with adverse outcomes [20].

The efficacy of anticholinergic agents, such as for prophylaxis for post-spinal hypotension in the non-obstetric field, has been demonstrated [110]. Nevertheless, there is insufficient data to warrant its use in obstetric practice. However, a high level of SA blocks the cardiac sympathetic nerve and causes the heart rate to decrease and the force of contraction to disappear. Therefore, simply increasing vasoconstriction might not effectively compensate for cardiac output. Atropine blocks the vagus nerve and drives up the heart rate [111].

Some studies suggest that ondansetron, a 5-hydroxytryptamine subtype 3 (5-HT<sub>3</sub>) receptor antagonist generally used for the prophylaxis and treatment of nausea and vomiting, may also reduce the hemodynamic changes induced by SA [112, 113]. Arterial hypotension and bradycardia can be caused by sympathetic nerve blockade and the Bezold–Jarisch reflex, mediated by peripheral serotonin receptors (5-HT<sub>3</sub> type). Therefore, IV administration of ondansetron, to block type 3 serotonin receptors, could reduce SA-induced hypotension and bradycardia. Accordingly, a meta-analysis provided evidence that 5-HT<sub>3</sub> antagonists are effective in reducing the incidence of hypotension and bradycardia. The effects were moderate and significant solely in the subgroup of patients undergoing cesarean delivery [114].

### **Prediction of hypotension**

The prediction of hypotension is based on the anesthesiologist's preoperative assessment, especially in parturients with coexisting pathologies or risk factors. However, in certain cases, spinal hypotension can be predicted by simple parameters, such as age, preoperative heart rate, and preoperative MAP (Kinsella et al. [2]).

### **Prefilled syringes**

The purchase of prefilled syringes with frequently prepared anesthetics has been suggested as a cost-saving measure [66]. Numerous studies have shown that avoidable waste is greatly reduced for drugs available in prefilled



syringes (phenylephrine and atropine) relative to drugs of the same class available in single-dose vials (ephedrine, glycopyrrolate) [66, 115–117]. In a study at an academic medical center, Atcheson compared the avoidable waste generated by phenylephrine and ephedrine to gain insight into the economic impact of using prefilled syringes [67]. During the study period, phenylephrine was available almost exclusively in prefilled syringes and was stored unopened but kept on hand in 76.6% of cases; it was wasted in only 2.6% of cases. Ephedrine was prepared for a similar proportion of cases (80.3%), but because it was compounded (filled) by the anesthesiologist in the operating room, ephedrine was wasted in three of five cases in which it was prepared. In addition, the difference in waste per case could have environmental implications [67]. Similar conclusions were drawn in another university obstetrics department, in which prefilled syringes significantly reduced ephedrine wastage, thus minimizing costs in obstetric anesthesia [118]. Prefilled syringes have advantages over standard syringes. They allow convenient and rapid administration of vasopressors during an emergency, saving time and lives. Medications stored in prefilled syringes remain sterile for 2–3 years. Prefilled syringes also improve the safety and accuracy of medication administration by leading to fewer dosing and medication errors [10, 11, 68, 119, 120].

#### **Current practice in the management of hypotension with vasopressors during cesarean section under SA: a Southeast Asia survey**

The survey containing 17 statements was distributed as an anonymous Delphi e-survey to peers in the Philippines, Thailand, and Vietnam. The participants were asked to provide their input on the choice of vasopressors for managing hypotension among parturients undergoing cesarean section under SA. An agreement was reached if at least 75% of participants scored the statement as “strongly agree” or “agree” on a four-grade rating scale. For those statements for which no consensus was reached, the statements were revised based on the voters’ comments, followed by a second round of voting. If no agreement was reached after two rounds of voting, the statement was excluded.

A total of 183 completed questionnaires were analyzed from the Philippines (69.4%,  $N = 127$ ), Vietnam (15.8%,  $N = 29$ ), and Thailand (14.7%,  $N = 27$ ). The vast majority of respondents agreed or strongly agreed with the following statements.

1. Hypotension during SA for cesarean delivery is common and must be recognized and treated immediately.

2. Prevention of spinal-induced hypotension is an important strategy to improve maternal and neonatal outcomes in cesarean deliveries. Fetal perfusion depends on uteroplacental blood flow, which lacks autoregulation so that it is directly dependent on uterine perfusion pressure and inversely proportional to uterine vascular resistance.
3. The duration of hypotension may be more important than its severity.
4. Systolic arterial pressure (SAP) must be maintained at  $\geq 90\%$  of an accurately measured baseline until delivery of the newborn to reduce the frequency and duration of episodes of significant hypotension to  $< 80\%$  of baseline.  $SAP < 80\%$  should be treated promptly, usually with a bolus injection of vasopressors. An SBP of  $> 90$  mmHg was acceptable. In preeclampsia or preexisting hypertension, the target blood pressure should be adjusted individually.
5. Bradycardia at SA for cesarean delivery may result in low cardiac output and must be treated promptly with atropine or anticholinergics.
6. To prevent hypotension during SA for cesarean delivery, concurrent measures must be taken.
7. Pre-spinal measures to prevent hypotension in parturients after SA include leg compression devices, manual left uterine displacement, and administration of 5HT<sub>3</sub> antagonists (e.g., ondansetron).
8. SA hypotension during cesarean delivery should be treated primarily with vasopressors complemented by fluid administration. Maternal and fetal outcomes are better when vasopressors are administered prophylactically rather than reactively to treat hypotension.
9. After successful SA, crystalloid co-loading and prophylactic administration of vasopressors should be started.

a. First choice: Phenylephrine administered:

- i. 1) Infusion (syringe pump/infusion device) began after administration of spinal anesthetic at 25–50  $\mu\text{g}/\text{min}$  titrated to blood pressure and heart rate. Therefore, additional IV boluses may be required.

OR

- ii. 2) As a bolus (ideally, use a prefilled syringe) after administration of SA without bradycardia. For immediate treatment of hypotension, an IV bolus of phenylephrine has a more rapid onset of action than an infusion.

b. Second choice: Ephedrine bolus administered upon administration of SA.

- c. Alternative choice considering availability: Noradrenaline (Norepinephrine) as an infusion/bolus in resource-limited areas (via central line or temporarily via a wide-bore peripheral line).
10. Crystalloid co-loading starts immediately before or at the start of SA.
11. Considering the availability, patient safety, cost, and benefits when choosing vasopressors for hypotension prevention and management (phenylephrine, ephedrine, norepinephrine, and epinephrine).
  - a. Phenylephrine is the first choice vasopressor agent for hypotension from SA for cesarean delivery in parturients with a normal heart rate.
  - b. Ephedrine is a vasopressor of choice in the presence of bradycardia.
  - c. Both epinephrine and norepinephrine are alternatives to correct hypotension and bradycardia unresponsive to ephedrine.
12. When hypotension persists despite aggressive intervention, causes other than sympathetic blockade should be considered.
13. Whether phenylephrine is administered as an infusion or bolus depends on the available resources at the institution, the cost, and the best practices agreed upon locally.
14. Single-dilution techniques using phenylephrine prefilled syringes or both should be considered and are preferable for patient safety.
15. Emergency cesarean delivery requires careful assessment of volume status with consideration of potential losses, including hemorrhage, vomiting, and prolonged labor. Significant hypovolemia is a contraindication for SA. Sympathectomy after SA can result in a potentially fatal reduction in venous return and cardiac preload.
16. Women with preeclampsia develop less hypotension than healthy women after SA. An abrupt drop in blood pressure is undesirable because it may result in decreased uteroplacental blood flow. A prophylactic vasopressor infusion may not be necessary; however, if used, it should be started at a lower rate than in healthy women.
17. Women with heart disease should be evaluated individually. Some conditions are best treated with phenylephrine (an arterial constrictor with no positive inotropic effects), whereas others respond best to ephedrine (which has positive inotropic and chronotropic effects).

## Regulatory considerations

The summary of healthcare systems in the Philippines, Thailand, and Vietnam; and the main challenges are summarized as follows (Table 2).

## Checklist for hypotension management

*Prophylactic vasopressor should be administered straight after SA.*

*Alpha-agonists are the most physiological, and phenylephrine is currently recommended.*

*Tilt the parturient 30° laterally and co-load the vasopressor with crystalloid.*

*Aim to maintain SBP > 90% baseline and avoid significant hypotension < 80% baseline.*

*When using variable rate infusion, start at 25–50 µg min<sup>-1</sup> phenylephrine, plus boluses PRN.*

*Administer phenylephrine bolus (prefilled syringe preferred) at 50–100 µg or ephedrine bolus at 5–15 mg.*

*Heart rate is a surrogate for cardiac output.*

*Use low doses of ephedrine for hypotension with low heart rate and anticholinergic for bradycardia.*

*Smart pumps provide greater stability.*

*If needed in case of preeclampsia, start vasopressors with lower doses.*

*Individualize the decision in the presence of cardiac conditions.*

*Refractory hypotension is individualized according to coexistent conditions contributing to shock, e.g., heart failure, arrhythmias, organ ischemia, or agent availability.*

*- Norepinephrine: agent of first choice*

*- Dobutamine for cardiogenic shock*

*- Epinephrine (adrenaline) for anaphylaxis*

*- Phenylephrine if tachyarrhythmia*

*Avoid vasopressin since it increases uterine contractions.*

*Avoid dopamine since it is associated with an increased risk of death (surviving sepsis campaign) in septic shock.*

## Recommendations for the management of hypotension after SA for cesarean section in limited-resource environments

### Choice of the vasopressor

After careful assessment of volume status and the exclusion of hypovolemia:

Phenylephrine is the vasopressor of choice, if available.

Infusion options if no syringe driver is available:

- No infusion: A bolus of 50–100 µg phenylephrine is required. Start treatment when heart rate increases, SBP decreases to 90% baseline, or both.

- Infusion: 500 µg phenylephrine is added to the first liter of Ringer's lactate and administered rapidly after SA.

**Table 2** Summary and main challenges of healthcare systems in the Philippines, Thailand, and Vietnam

Philippines	Thailand	Vietnam
Phenylephrine is not listed in the Philippine National Drug Formulary (PNDF) but is available in the Philippine market on the rationale of “compassionate use.” The Philippine National Health Insurance (Philhealth) <i>reimburses only PNDF-listed medications used by patients</i> . Non-PNDF medications are paid out-of-pocket by patients in public hospitals. Therefore, it remains an additional financial burden for the patient. The higher cost is an issue compared to that of ephedrine	Phenylephrine is new and recently included in Thailand’s Diagnostic Related Group. However, anesthesiologists are concerned about the wasted cost of the unused drug when prepared in anticipation of use. The prefilled syringe can be cost-saving. Nor-epinephrine and epinephrine are used in some hospitals when phenylephrine is not available	Phenylephrine is registered but is limited to specialty hospitals. This deprives smaller community hospitals of medications like phenylephrine. On the other hand, ephedrine is cheap and widely available. Recently, Vietnamese health care insurance has inserted phenylephrine into the drug list. It means that insurers pay for this drug

Administration for 10–20 min is approximately equivalent to an infusion of 25–50 µg/min and can be titrated according to heart rate and blood pressure responses.

Alternative options:

- Ephedrine (50 mg) added to 10 ml 0.9% saline in a 10-ml syringe (5 mg/ml): Bolus dose of 10 mg.
- Adrenaline (0.5 mg) added to 100 ml 0.9% saline (5 µg/ml): Bolus dose of 10 µg.

### Monitoring

The following values should be recorded (repeat the baseline measurements if they are outside the normal range):

1. Baseline SAP
2. 90% baseline SAP

3.80% baseline SAP

### At the end of the SA injection

Commence vasopressor infusion at a predetermined starting rate.


Set NIBP measurements to 1 min cycles or perform manual BP measurements every 1 min until SBP is stable or the baby is delivered.

Start IV crystalloid co-loading: 15 ml/kg (titrated accordingly).

Treat hypotension early and aggressively. Aim to keep the SAP ≥ 90% of baseline SAP and heart rate ≤ 120% of baseline.

Be cautious for patients with heart failure, kidney disease, or congestion.

### Management techniques scheme (Fig. 2)



## Acknowledgements

The authors acknowledge the valuable contributions of CopperMed Health Ltd. in the development, writing, and editing of the manuscript.

## Author's contributions

GH and CT conceptualized the idea for the study and coordinated the expert consensus. GH, NT, AG, SL, and CT designed the search strategy and reviewed the correct consensus methodology. All authors voted for the clinical questions and statements and reviewed the manuscript. All authors agreed to be responsible for all aspects of the work. The authors read the final version of the manuscript and gave their final approval.

## Funding

This research received no external funding.

## Availability of data and materials

The data of the present expert consensus are available at reasonable request from the corresponding author.

## Declarations

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Competing interests

All authors have received consultancy fees/honoraria from Aguetant.

## Author details

<sup>1</sup>Department of Anesthesiology, University of the Philippines College of Medicine, Manila, Philippines. <sup>2</sup>Department of Anesthesiology and Intensive Care, Hanoi French Hospital, Hanoi, Vietnam. <sup>3</sup>Department of Anesthesiology, Divine Word Hospital, Tacloban, Philippines. <sup>4</sup>Department of Anesthesiology, Faculty of Medicine, Chiang Mai University Hospital, Chang Mai, Thailand. <sup>5</sup>Vietnam Society of Anesthesiologists, Head of Department of Anesthesiology and SCIU at HuuNghi Hospital, Hanoi, Vietnam.

Received: 12 August 2022 Accepted: 8 December 2022

Published online: 28 December 2022

## References

- Halperin JL, Levine GN, Al-Khatib SM et al (2016) Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 133:1426–1428. <https://doi.org/10.1161/CIR.0000000000000312>
- Kinsella SM, Carvalho B, Dyer RA et al (2018) International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. *Anaesthesia* 73:71–92. <https://doi.org/10.1111/anae.14080>
- Bollag L, Lim G, Sultan P et al (2021) Society for Obstetric Anesthesia and Perinatology: Consensus Statement and Recommendations for Enhanced Recovery After Cesarean. *Anesth Analg* 132:1362–1377. <https://doi.org/10.1213/ANE.00000000000005257>
- Singh PM, Singh NP, Reschke M et al (2020) Vasopressor drugs for the prevention and treatment of hypotension during neuraxial anaesthesia for Caesarean delivery: a Bayesian network meta-analysis of fetal and maternal outcomes. *Br J Anaesth* 124:e95–e107. <https://doi.org/10.1016/j.bja.2019.09.045>
- (2016) Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. *Anesthesiology* 124:270–300. <https://doi.org/10.1097/ALN.0000000000000935>
- Fitzgerald JP, Fedoruk KA, Jadin SM et al (2020) Prevention of hypotension after spinal anaesthesia for caesarean section: a systematic review and network meta-analysis of randomised controlled trials. *Anaesthesia* 75:109–121. <https://doi.org/10.1111/anae.14841>
- Heesen M, Köhr S, Rossaint R, Straube S (2014) Prophylactic phenylephrine for caesarean section under spinal anaesthesia: systematic review and meta-analysis. *Anaesthesia* 69:143–165. <https://doi.org/10.1111/anae.12445>
- Allen TK, George RB, White WD et al (2010) A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. *Anesth Analg* 111:1221–1229. <https://doi.org/10.1213/ANE.0b013e3181e1db21>
- Makwana S, Basu B, Makasana Y, Dharamsi A (2011) Prefilled syringes: An innovation in parenteral packaging. *Int J Pharm Investig* 1:200–206. <https://doi.org/10.4103/2230-973X.93004>
- Mahajan RP (2011) Medication errors: can we prevent them? *Br J Anaesth* 107:3–5. <https://doi.org/10.1093/bja/aer131>
- Cole JB, Knack SK, Karl ER et al (2019) Human Errors and Adverse Hemodynamic Events Related to “Push Dose Pressors” in the Emergency Department. *J Med Toxicol* 15:276–286. <https://doi.org/10.1007/s13181-019-00716-z>
- Dyer RA, Reed AR, van Dyk D et al (2009) Hemodynamic effects of ephedrine, phenylephrine, and the coadministration of phenylephrine with oxytocin during spinal anesthesia for elective cesarean delivery. *Anesthesiology* 111:753–765. <https://doi.org/10.1097/ALN.0b013e3181b437e0>
- Butwick AJ, Columb MO, Carvalho B (2015) Preventing spinal hypotension during Caesarean delivery: what is the latest? *Br J Anaesth* 114:183–186. <https://doi.org/10.1093/bja/aeu267>
- Kinsella SM (2003) Lateral tilt for pregnant women: why 15 degrees? *Anaesthesia* 58:835–836. <https://doi.org/10.1046/j.1365-2044.2003.03397.x>
- Rout CC, Rocke DA, Gouws E (1993) Leg elevation and wrapping in the prevention of hypotension following spinal anaesthesia for elective caesarean section. *Anaesthesia* 48:304–308. <https://doi.org/10.1111/j.1365-2044.1993.tb06948.x>
- Kinsella SM, Pirllet M, Mills MS et al (2000) Randomized study of intravenous fluid preload before epidural analgesia during labour. *Br J Anaesth* 85:311–313. <https://doi.org/10.1093/bja/85.2.311>
- Kubli M, Shennan AH, Seed PT, O'Sullivan G (2003) A randomised controlled trial of fluid pre-loading before low dose epidural analgesia for labour. *Int J Obstet Anesth* 12:256–260. [https://doi.org/10.1016/S0959-289X\(03\)00071-2](https://doi.org/10.1016/S0959-289X(03)00071-2)
- Ngan Kee WD, Lee SWY, Ng FF et al (2015) Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery. *Anesthesiology* 122:736–745. <https://doi.org/10.1097/ALN.0000000000000601>
- Vallejo MC, Attaallah AF, Elzamzamy OM et al (2017) An open-label randomized controlled clinical trial for comparison of continuous phenylephrine versus norepinephrine infusion in prevention of spinal hypotension during cesarean delivery. *Int J Obstet Anesth* 29:18–25. <https://doi.org/10.1016/j.ijoa.2016.08.005>
- Onwochei DN, Ngan Kee WD, Fung L et al (2017) Norepinephrine Intermittent Intravenous Boluses to Prevent Hypotension During Spinal Anesthesia for Cesarean Delivery: A Sequential Allocation Dose-Finding Study. *Anesth Analg* 125:212–218. <https://doi.org/10.1213/ANE.0000000000001846>
- Ngan Kee WD, Lee SWY, Ng FF, Khaw KS (2018) Prophylactic Norepinephrine Infusion for Preventing Hypotension During Spinal Anesthesia for Cesarean Delivery. *Anesth Analg* 126:1989–1994. <https://doi.org/10.1213/ANE.0000000000002243>
- Patel SD, Habib AS, Phillips S et al (2018) The Effect of Glycopyrrlate on the Incidence of Hypotension and Vasopressor Requirement During Spinal Anesthesia for Cesarean Delivery: A Meta-analysis. *Anesth Analg* 126:552–558. <https://doi.org/10.1213/ANE.0000000000002274>
- Eltzschig HK, Lieberman ES, Camann WR (2003) Regional anesthesia and analgesia for labor and delivery. *N Engl J Med* 348:319–332. <https://doi.org/10.1056/NEJMr021276>



24. Cyna AM, Andrew M, Emmett RS, et al (2006) Techniques for preventing hypotension during spinal anaesthesia for caesarean section. *Cochrane Database Syst Rev* CD002251. <https://doi.org/10.1002/14651858.CD002251.pub2>
25. Prakash S, Pramanik V, Chellani H et al (2010) Maternal and neonatal effects of bolus administration of ephedrine and phenylephrine during spinal anaesthesia for caesarean delivery: a randomised study. *Int J Obstet Anesth* 19:24–30. <https://doi.org/10.1016/j.ijoa.2009.02.007>
26. Langesaeter E, Dyer RA (2011) Maternal haemodynamic changes during spinal anaesthesia for caesarean section. *Curr Opin Anaesthesiol* 24:242–248. <https://doi.org/10.1097/ACO.0b013e32834588c5>
27. Lim G, Facco FL, Nathan N et al (2018) A Review of the Impact of Obstetric Anesthesia on Maternal and Neonatal Outcomes. *Anesthesiology* 129:192–215. <https://doi.org/10.1097/ALN.0000000000002182>
28. Jeon JY, Lee IH, Jee YS et al (2014) The effects on Apgar scores and neonatal outcomes of switching from a combination of phenylephrine and ephedrine to phenylephrine alone as a prophylactic vasopressor during spinal anesthesia for cesarean section. *Korean J Anesthesiol* 67:38–42. <https://doi.org/10.4097/kjae.2014.67.1.38>
29. Ralston DH, Shnider SM, DeLorimier AA (1974) Effects of equipotent ephedrine, metaraminol, mephentermine, and methoxamine on uterine blood flow in the pregnant ewe. *Anesthesiology* 40:354–370. <https://doi.org/10.1097/0000542-197404000-00009>
30. Ngan Kee WD, Khaw KS, Lee BB et al (2001) Randomized controlled study of colloid preload before spinal anaesthesia for caesarean section. *Br J Anaesth* 87:772–774. <https://doi.org/10.1093/bja/87.5.772>
31. Lee A, Ngan Kee WD, Gin T (2002) A quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean delivery. *Anesth Analg* 94:920–926, table of contents. <https://doi.org/10.1097/0000539-200204000-00028>
32. Weiner CP, Martinez E, Chestnut DH, Ghodsi A (1989) Effect of pregnancy on uterine and carotid artery response to norepinephrine, epinephrine, and phenylephrine in vessels with documented functional endothelium. *Am J Obstet Gynecol* 161:1605–1610. [https://doi.org/10.1016/0002-9378\(89\)90934-4](https://doi.org/10.1016/0002-9378(89)90934-4)
33. Ngan Kee WD, Khaw KS, Ng FF (2004) Comparison of phenylephrine infusion regimens for maintaining maternal blood pressure during spinal anaesthesia for Caesarean section. *Br J Anaesth* 92:469–474. <https://doi.org/10.1093/bja/ae088>
34. Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 372:n71. <https://doi.org/10.1136/bmj.n71>
35. Klöhr S, Roth R, Hofmann T et al (2010) Definitions of hypotension after spinal anaesthesia for caesarean section: literature search and application to parturients. *Acta Anaesthesiol Scand* 54:909–921. <https://doi.org/10.1111/j.1399-6576.2010.02239.x>
36. Ngan Kee WD, Khaw KS, Ng FF (2005) Prevention of hypotension during spinal anesthesia for caesarean delivery: an effective technique using combination phenylephrine infusion and crystalloid cohydration. *Anesthesiology* 103:744–750. <https://doi.org/10.1097/0000542-200510000-00012>
37. Ngan Kee WD, Lee A, Khaw KS et al (2008) A randomized double-blinded comparison of phenylephrine and ephedrine infusion combinations to maintain blood pressure during spinal anesthesia for cesarean delivery: the effects on fetal acid-base status and hemodynamic control. *Anesth Analg* 107:1295–1302. <https://doi.org/10.1213/ane.0b013e31818065bc>
38. Langesaeter E, Rosseland LA, Stubhaug A (2008) Continuous invasive blood pressure and cardiac output monitoring during caesarean delivery: a randomized, double-blind comparison of low-dose versus high-dose spinal anesthesia with intravenous phenylephrine or placebo infusion. *Anesthesiology* 109:856–863. <https://doi.org/10.1097/ALN.0b013e31818a401f>
39. George RB, McKeen D, Columb MO, Habib AS (2010) Up-down determination of the 90% effective dose of phenylephrine for the treatment of spinal anesthesia-induced hypotension in parturients undergoing cesarean delivery. *Anesth Analg* 110:154–158. <https://doi.org/10.1213/ANE.0b013e3181c30b72>
40. Burns SM, Cowan CM, Wilkes RG (2001) Prevention and management of hypotension during spinal anaesthesia for elective Caesarean section: a survey of practice. *Anaesthesia* 56:794–798. <https://doi.org/10.1046/j.1365-2044.2001.02058-5.x>
41. Ashagrie HE, Filatie TD, Melesse DY, Mustefa S (2020) The incidence and factors associated with intraoperative nausea and vomiting during cesarean section under spinal anesthesia, July 2019. An institution based cross sectional study. *International Journal of Surgery Open* 26:49–54. <https://doi.org/10.1016/j.ijso.2020.08.007>
42. Borgeat A, Ekatodramis G, Schenker CA (2003) Postoperative nausea and vomiting in regional anesthesia: a review. *Anesthesiology* 98:530–547. <https://doi.org/10.1097/0000542-200302000-00036>
43. Hirose N, Kondo Y, Maeda T et al (2016) Relationship between regional cerebral blood volume and oxygenation and blood pressure during spinal anesthesia in women undergoing cesarean section. *J Anesth* 30:603–609. <https://doi.org/10.1007/s00540-016-2165-6>
44. Ratra CK, Badola RP, Bhargava KP (1972) A study of factors concerned in emesis during spinal anaesthesia. *Br J Anaesth* 44:1208–1211. <https://doi.org/10.1093/bja/44.11.1208>
45. Hirose N, Kondo Y, Maeda T et al (2016) Oxygen Supplementation is Effective in Attenuating Maternal Cerebral Blood Deoxygenation After Spinal Anesthesia for Cesarean Section. *Adv Exp Med Biol* 876:471–477. [https://doi.org/10.1007/978-1-4939-3023-4\\_59](https://doi.org/10.1007/978-1-4939-3023-4_59)
46. Šklebar I, Bujas T, Habek D (2019) SPINAL ANAESTHESIA-INDUCED HYPOTENSION IN OBSTETRICS: PREVENTION AND THERAPY. *Acta Clin Croat* 58:90–95. <https://doi.org/10.20471/acc.2019.58.s1.13>
47. Cooperman LH (1972) Effects of anaesthetics on the splanchnic circulation. *Br J Anaesth* 44:967–970. <https://doi.org/10.1093/bja/44.9.967>
48. Liu S, Carpenter RL, Neal JM (1995) Epidural anesthesia and analgesia. Their role in postoperative outcome. *Anesthesiology* 82:1474–1506. <https://doi.org/10.1097/0000542-199506000-00019>
49. Ferré F, Martin C, Bosch L et al (2020) Control of Spinal Anesthesia-Induced Hypotension in Adults. *Local Reg Anesth* 13:39–46. <https://doi.org/10.2147/LRA.S240753>
50. Corke BC, Datta S, Ostheimer GW et al (1982) Spinal anaesthesia for Caesarean section. The influence of hypotension on neonatal outcome. *Anaesthesia* 37:658–662. <https://doi.org/10.1111/j.1365-2044.1982.tb01278.x>
51. Nag DS, Samaddar DP, Chatterjee A, et al (2015) Vasopressors in obstetric anesthesia: A current perspective. *World J Clin Cases* 3:58–64. <https://doi.org/10.12998/wjcc.v3.i1.58>
52. Wang YB, Yang ZY, Zhang WP (2020) Comparison of Continuous Infusion of Epinephrine and Phenylephrine on Hemodynamics During Spinal Anesthesia for Cesarean Delivery: A Randomized Controlled Trial. *Clin Ther* 42:2001–2009. <https://doi.org/10.1016/j.clinthera.2020.08.004>
53. Ali Elnabity AM, Selim MF (2018) Norepinephrine versus Ephedrine to Maintain Arterial Blood Pressure during Spinal Anesthesia for Cesarean Delivery: A Prospective Double-blinded Trial. *Anesth Essays Res* 12:92–97. [https://doi.org/10.4103/aer.AER\\_204\\_17](https://doi.org/10.4103/aer.AER_204_17)
54. Westfall TC, Macarthur H, Westfall DP (2017) Adrenergic Agonists and Antagonists. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds) Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13th edn. McGraw-Hill Education, New York, NY
55. Stewart A, Fernando R, McDonald S et al (2010) The dose-dependent effects of phenylephrine for elective caesarean delivery under spinal anesthesia. *Anesth Analg* 111:1230–1237. <https://doi.org/10.1213/ANE.0b013e3181f2eae1>
56. McCorry LK (2007) Physiology of the autonomic nervous system. *Am J Pharm Educ* 71:78. <https://doi.org/10.5688/aj710478>
57. Tanaka M, Balki M, Parkes RK, Carvalho JCA (2009) ED95 of phenylephrine to prevent spinal-induced hypotension and/or nausea at elective caesarean delivery. *Int J Obstet Anesth* 18:125–130. <https://doi.org/10.1016/j.ijoa.2008.09.008>
58. Habib AS (2012) A review of the impact of phenylephrine administration on maternal hemodynamics and maternal and neonatal outcomes in women undergoing caesarean delivery under spinal anesthesia. *Anesth Analg* 114:377–390. <https://doi.org/10.1213/ANE.0b013e3182373a3e>
59. Reidy J, Douglas J (2008) Vasopressors in obstetrics. *Anesthesiol Clin* 26(75–88):vi–vii. <https://doi.org/10.1016/j.janclin.2007.11.005>
60. Kee VR (2003) Hemodynamic pharmacology of intravenous vasopressors. *Crit Care Nurse* 23:79–82

61. Ngan Kee WD, Khaw KS, Tan PE et al (2009) Placental transfer and fetal metabolic effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. *Anesthesiology* 111:506–512. <https://doi.org/10.1097/ALN.0b013e3181b160a3>
62. Kol IO, Kaygusuz K, Gursoy S et al (2009) The effects of intravenous ephedrine during spinal anesthesia for cesarean delivery: a randomized controlled trial. *J Korean Med Sci* 24:883–888. <https://doi.org/10.3346/jkms.2009.24.5.883>
63. Mohta M, Garg A, Chilkoti GT, Malhotra RK (2019) A randomised controlled trial of phenylephrine and noradrenaline boluses for treatment of postspinal hypotension during elective caesarean section. *Anaesthesia* 74:850–855. <https://doi.org/10.1111/anae.14675>
64. Skillman CA, Plessinger MA, Woods JR, Clark KE (1985) Effect of graded reductions in uteroplacental blood flow on the fetal lamb. *Am J Physiol* 249:H1098–H1105. <https://doi.org/10.1152/ajpheart.1985.249.6.H1098>
65. Gibbs MW, van Dyk D, Dyer RA (2018) Managing spinal hypotension during caesarean section: An update. *S Afr Med J* 108:460–463. <https://doi.org/10.7196/SAMJ.2018.v108i6.13373>
66. McCook A (2011) Prefilled syringes cut waste — and bottom line on drugs. *Anesthesiol News* 37. <https://www.anesthesiologynews.com/PrintArticle/19192>
67. Atcheson CLH, Spivack J, Williams R, Bryson EO (2016) Preventable drug waste among anesthesia providers: opportunities for efficiency. *J Clin Anesth* 30:24–32. <https://doi.org/10.1016/j.jclinane.2015.12.005>
68. Whitaker D, Brattebo G, Trenkler S et al (2017) The European Board of Anaesthesiology recommendations for safe medication practice: First update. *Eur J Anaesthesiol* 34:4–7. <https://doi.org/10.1097/EJA.0000000000000531>
69. Veesser M, Hofmann T, Roth R et al (2012) Vasopressors for the management of hypotension after spinal anesthesia for elective caesarean section. Systematic review and cumulative meta-analysis. *Acta Anaesthesiol Scand* 56:810–816. <https://doi.org/10.1111/j.1399-6576.2011.02646.x>
70. Doherty A, Ohashi Y, Downey K, Carvalho JCA (2012) Phenylephrine infusion versus bolus regimens during cesarean delivery under spinal anesthesia: a double-blind randomized clinical trial to assess hemodynamic changes. *Anesth Analg* 115:1343–1350. <https://doi.org/10.1213/ANE.0b013e31826ac3db>
71. Choudhary M, Bajaj JK (2018) Study Comparing Phenylephrine Bolus and Infusion for Maternal Hypotension and Neonatal Outcome during Cesarean Section under Spinal Anesthesia. *Anesth Essays Res* 12:446–451. [https://doi.org/10.4103/aer.AER\\_23\\_18](https://doi.org/10.4103/aer.AER_23_18)
72. Hasanin A, Habib S, Abdelwahab Y et al (2019) Variable versus fixed-rate infusion of phenylephrine during cesarean delivery: a randomized controlled trial. *BMC Anesthesiol* 19:197. <https://doi.org/10.1186/s12871-019-0879-3>
73. Webb AA, Shipton EA (1998) Re-evaluation of i.m. ephedrine as prophylaxis against hypotension associated with spinal anaesthesia for Caesarean section. *Can J Anaesth* 45:367–369. <https://doi.org/10.1007/BF03012030>
74. Ngan Kee WD, Khaw KS, Lee BB et al (2000) A dose-response study of prophylactic intravenous ephedrine for the prevention of hypotension during spinal anesthesia for cesarean delivery. *Anesth Analg* 90:1390–1395. <https://doi.org/10.1097/00000539-200006000-00024>
75. Vercauteren MP, Coppejans HC, Hoffmann VH et al (2000) Prevention of hypotension by a single 5-mg dose of ephedrine during small-dose spinal anesthesia in prehydrated cesarean delivery patients. *Anesth Analg* 90:324–327. <https://doi.org/10.1097/00000539-200002000-00016>
76. Loughrey JPR, Walsh F, Gardiner J (2002) Prophylactic intravenous bolus ephedrine for elective Caesarean section under spinal anaesthesia. *Eur J Anaesthesiol* 19:63–68. <https://doi.org/10.1017/s0265021502000108>
77. Stratton L, Berlin DA, Arbo JE (2017) Vasopressors and Inotropes in Sepsis. *Emerg Med Clin North Am* 35:75–91. <https://doi.org/10.1016/j.emc.2016.09.005>
78. Tian DH, Smyth C, Keijzers G et al (2020) Safety of peripheral administration of vasopressor medications: A systematic review. *Emerg Med Australas* 32:220–227. <https://doi.org/10.1111/1742-6723.13406>
79. Walker SE, Law S, Garland J et al (2010) Stability of norepinephrine solutions in normal saline and 5% dextrose in water. *Can J Hosp Pharm* 63:113–118. <https://doi.org/10.4212/cjhp.v63i2.896>
80. Ekeløf NP, Jensen E, Poulsen J, Reinstrup P (1997) Weight gain during pregnancy does not influence the spread of spinal analgesia in the term parturient. *Acta Anaesthesiol Scand* 41:884–887. <https://doi.org/10.1111/j.1399-6576.1997.tb04804.x>
81. Hartwell BL, Aglio LS, Hauch MA, Datta S (1991) Vertebral column length and spread of hyperbaric subarachnoid bupivacaine in the term parturient. *Reg Anesth* 16:17–19
82. Norris MC (1990) Patient variables and the subarachnoid spread of hyperbaric bupivacaine in the term parturient. *Anesthesiology* 72:478–482. <https://doi.org/10.1097/00000542-199003000-00015>
83. Huang B, Huang Q, Hai C et al (2019) Height-based dosing algorithm of bupivacaine in spinal anaesthesia for decreasing maternal hypotension in caesarean section without prophylactic fluid preloading and vasopressors: study protocol for a randomised controlled non-inferiority trial. *BMJ Open* 9:e024912. <https://doi.org/10.1136/bmjopen-2018-024912>
84. Greene NM (1985) Distribution of local anesthetic solutions within the subarachnoid space. *Anesth Analg* 64:715–730
85. Danelli G, Zangrillo A, Nucera D et al (2001) The minimum effective dose of 0.5% hyperbaric spinal bupivacaine for cesarean section. *Minerva Anesthesiol* 67:573–577
86. Pitkänen MT (1987) Body mass and spread of spinal anesthesia with bupivacaine. *Anesth Analg* 66:127–131
87. Arzola C, Wieczorek PM (2011) Efficacy of low-dose bupivacaine in spinal anaesthesia for Caesarean delivery: systematic review and meta-analysis. *Br J Anaesth* 107:308–318. <https://doi.org/10.1093/bja/aer200>
88. Chekol WB, Melesse DY, Mersha AT (2021) Incidence and factors associated with hypotension in emergency patients that underwent cesarean section with spinal anaesthesia: Prospective observational study. *International Journal of Surgery Open* 35:100378. <https://doi.org/10.1016/j.ijso.2021.100378>
89. Wang X, Xu J-M, Zhou F, et al (2015) Maternal position and development of hypotension in patients undergoing cesarean section under combined spinal-epidural anesthesia of intrathecal hyperbaric ropivacaine. *Med Sci Monit* 21:52–58. <https://doi.org/10.12659/MSM.892224>
90. Obasuyi BI, Fyeneface-Ogan S, Mato CN (2013) A comparison of the haemodynamic effects of lateral and sitting positions during induction of spinal anaesthesia for caesarean section. *Int J Obstet Anesth* 22:124–128. <https://doi.org/10.1016/j.ijoa.2012.12.005>
91. Kundra P, Velraj J, Amirthalangam U et al (2012) Effect of positioning from supine and left lateral positions to left lateral tilt on maternal blood flow velocities and waveforms in full-term parturients. *Anaesthesia* 67:889–893. <https://doi.org/10.1111/j.1365-2044.2012.07164.x>
92. Siriussawakul A, Triyasunant N, Nimmannit A et al (2014) Effects of supplemental oxygen on maternal and neonatal oxygenation in elective cesarean section under spinal anaesthesia: a randomized controlled trial. *Biomed Res Int* 2014:627028. <https://doi.org/10.1155/2014/627028>
93. Kelly MC, Fitzpatrick KT, Hill DA (1996) Respiratory effects of spinal anaesthesia for caesarean section. *Anaesthesiology* 51:1120–1122. <https://doi.org/10.1111/j.1365-2044.1996.tb15046.x>
94. Cobb B, Cho Y, Hilton G et al (2016) Active Warming Utilizing Combined IV Fluid and Forced-Air Warming Decreases Hypothermia and Improves Maternal Comfort During Cesarean Delivery: A Randomized Control Trial. *Anesth Analg* 122:1490–1497. <https://doi.org/10.1213/ANE.0000000000001181>
95. Nair A (2016) The effect of patient warming during Caesarean delivery on maternal and neonatal outcomes: a meta-analysis. *Br J Anaesth* 117:676. <https://doi.org/10.1093/bja/aew323>
96. Butwick AJ, Lipman SS, Carvalho B (2007) Intraoperative forced air-warming during cesarean delivery under spinal anesthesia does not prevent maternal hypothermia. *Anesth Analg* 105:1413–1419, table of contents. <https://doi.org/10.1213/01.ane.0000286167.96410.27>
97. Matsukawa T, Sessler DI, Sessler AM et al (1995) Heat flow and distribution during induction of general anesthesia. *Anesthesiology* 82:662–673. <https://doi.org/10.1097/00000542-199503000-00008>
98. Sessler DI (2000) Perioperative heat balance. *Anesthesiology* 92:578–596. <https://doi.org/10.1097/00000542-200002000-00042>
99. Cotoia A, Mariotti PS, Ferialdi C et al (2021) Effectiveness of Combined Strategies for the Prevention of Hypothermia Measured by Noninvasive Zero-Heat Flux Thermometer During Cesarean Section. *Front Med (Lausanne)* 8:734768. <https://doi.org/10.3389/fmed.2021.734768>

100. Rauch S, Miller C, Bräuer A et al (2021) Perioperative Hypothermia-A Narrative Review. *Int J Environ Res Public Health* 18:8749. <https://doi.org/10.3390/ijerph18168749>
101. Mercier FJ, Augè M, Hoffmann C et al (2013) Maternal hypotension during spinal anesthesia for caesarean delivery. *Minerva Anestesiologica* 79:62–73
102. Mercier FJ, Diemunsch P, Ducloy-Bouthors A-S et al (2014) 6% Hydroxyethyl starch (130/0.4) vs Ringer's lactate preloading before spinal anaesthesia for Caesarean delivery: the randomized, double-blind, multicentre CAESAR trial. *Br J Anaesth* 113:459–467. <https://doi.org/10.1093/bja/aeu103>
103. Ni H-F, Liu H-Y, Zhang J et al (2017) Crystalloid Coload Reduced the Incidence of Hypotension in Spinal Anesthesia for Cesarean Delivery, When Compared to Crystalloid Preload: A Meta-Analysis. *Biomed Res Int* 2017:3462529. <https://doi.org/10.1155/2017/3462529>
104. Staikou C, Paraskeva A, Karmanioliou I et al (2014) Current practice in obstetric anesthesia: a 2012 European survey. *Minerva Anestesiologica* 80:347–354
105. Coe AJ, Revanäs B (1990) Is crystalloid preloading useful in spinal anaesthesia in the elderly? *Anaesthesia* 45:241–243. <https://doi.org/10.1111/j.1365-2044.1990.tb14696.x>
106. Rout CC, Akoojee SS, Rocke DA, Gouws E (1992) Rapid administration of crystalloid preload does not decrease the incidence of hypotension after spinal anaesthesia for elective caesarean section. *Br J Anaesth* 68:394–397. <https://doi.org/10.1093/bja/68.4.394>
107. Ueyama H, He YL, Tanigami H et al (1999) Effects of crystalloid and colloid preload on blood volume in the parturient undergoing spinal anesthesia for elective Cesarean section. *Anesthesiology* 91:1571–1576. <https://doi.org/10.1097/00000542-199912000-00006>
108. Pouta AM, Karinen J, Vuolteenaho OJ, Laatikainen TJ (1996) Effect of intravenous fluid preload on vasoactive peptide secretion during Cesarean section under spinal anaesthesia. *Anaesthesia* 51:128–132. <https://doi.org/10.1111/j.1365-2044.1996.tb07698.x>
109. Ngan Kee WD, Lau TK, Khaw KS, Lee BB (2001) Comparison of metaraminol and ephedrine infusions for maintaining arterial pressure during spinal anesthesia for elective cesarean section. *Anesthesiology* 95:307–313. <https://doi.org/10.1097/00000542-200108000-00009>
110. Jain SA, Kaushik A (2016) Assessment of Prophylactic Effect of Atropine with Ephedrine in Prevention of Hypotension Induced by Spinal Anaesthesia in Elderly Patients: A Comparative Study. *Int J Med Res Prof* 2:174–178. <https://doi.org/10.21276/IJMRP.2016.2.4.042>
111. Luo X-J, Zheng M, Tian G et al (2016) Comparison of the treatment effects of methoxamine and combining methoxamine with atropine infusion to maintain blood pressure during spinal anesthesia for cesarean delivery: a double blind randomized trial. *Eur Rev Med Pharmacol Sci* 20:561–567
112. Owczuk R, Wenski W, Polak-Krzeminska A et al (2008) Ondansetron Given Intravenously Attenuates Arterial Blood Pressure Drop Due to Spinal Anesthesia: A Double-Blind, Placebo-Controlled Study. *Reg Anesth Pain Med* 33:332–339. <https://doi.org/10.1136/rapm-00115550-200807000-00008>
113. Gao L, Zheng G, Han J et al (2015) Effects of prophylactic ondansetron on spinal anesthesia-induced hypotension: a meta-analysis. *Int J Obstet Anesth* 24:335–343. <https://doi.org/10.1016/j.ijoa.2015.08.012>
114. Heesen M, Klimek M, Hoeks SE, Rossaint R (2016) Prevention of Spinal Anesthesia-Induced Hypotension During Cesarean Delivery by 5-Hydroxytryptamine-3 Receptor Antagonists: A Systematic Review and Meta-analysis and Meta-regression. *Anesth Analg* 123:977–988. <https://doi.org/10.1213/ANE.0000000000001511>
115. Gillerman RG, Browning RA (2000) Drug use inefficiency: a hidden source of wasted health care dollars. *Anesth Analg* 91:921–924. <https://doi.org/10.1097/00000539-200010000-00028>
116. Nava-Ocampo AA, Alarcón-Almanza JM, Moyao-García D et al (2004) Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. *Fundam Clin Pharmacol* 18:107–112. <https://doi.org/10.1046/j.0767-3981.2003.00214.x>
117. Vipond A, De Mello W (2000) Drugs used in anaesthetic emergencies: current practice and a cost analysis of prefilled syringes. *Anaesthesia* 55:303–304. <https://doi.org/10.1046/j.1365-2044.2000.01352.x>
118. Bellefleur J-P, Milhaud Y, Beconcini G et al (2009) Use of ephedrine prefilled syringes reduces anesthesia costs. *Ann Fr Anesth Reanim* 28:211–214. <https://doi.org/10.1016/j.jannfar.2008.12.004>
119. Glavin RJ (2010) Drug errors: consequences, mechanisms, and avoidance. *Br J Anaesth* 105:76–82. <https://doi.org/10.1093/bja/aeq131>
120. Wahr JA, Abernathy JH, Lazarra EH et al (2017) Medication safety in the operating room: literature and expert-based recommendations. *Br J Anaesth* 118:32–43. <https://doi.org/10.1093/bja/aew379>

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

